Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes

Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2017-10, Vol.33 (sup2), p.19-31
Main Authors: Currie, Craig J., Holden, Sarah E., Berni, Ellen, Owens, David R.
Format: Article
Language:English
Subjects:
Aged
Cohort Studies
diabetic macular edema
Diabetic Retinopathy - drug therapy
Drug Implants
fellow eye
Female
Fluocinolone acetonide
Fluocinolone Acetonide - therapeutic use
Glucocorticoids - therapeutic use
Humans
Intraocular Pressure
Macular Edema - drug therapy
Male
Middle Aged
retrospective
Retrospective Studies
study eye
Treatment Outcome
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in the UK (ICE-UK) study. Methods: In this retrospective cohort study, data on people attending hospital eye services and treated with the FAc implant between April 1, 2013 and April 15, 2015 were collected. Changes in visual acuity (VA), central foveal thickness (CFT) and intraocular pressure (IOP) were compared between study eyes (intervention) and fellow eyes. Results: A total of 208 people were selected. Mean age was 68.1 years and 62% were male. Mean change in VA was −0.09 LogMAR units for study eyes and 0.04 LogMAR units for fellow eyes at 12 months post-implant (p 
ISSN:0300-7995
1473-4877
DOI:10.1080/03007995.2017.1366659